Michael Boland, MD, AGS 22: Findings of Clinical Trials and Future Emerging Technologies
We were delighted to speak with Prof. Michael Boland (Massachusetts Eye and Ear, Boston, MA, USA) about the findings of clinical trials investigating methods of assessing disease progression and emerging technologies in the future.
The presentation entitled ‘Measuring Disease Progression in Clinical Trials’ was presented at the 2022 American Glaucoma Society Annual Meeting, March 03-06, 2022.
Disclosures: Michael Boland is a consultant for Carl Zeiss Meditec, Topcon and Allergan
- What clinical trials are investigating methods of assessing disease progression? (00:21)
- What have been the findings of studies to date? (01:17)
- What emerging technologies do you expect to be useful in the future? (02:24)
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Shanice Allen.
Filmed in coverage of the virtual AGS 2022.
Share this Video
Related Videos In Glaucoma
Ticiana De Francesco, AGS 2023: Corneal endothelial cell safety profile of three different MiGS stents
Endothelial cell safety is an important factor to consider when selecting early surgical treatment for glaucoma patients. It was a pleasure to speak with Dr Ticiana De Francesco (Hospital de Olhos Leiria de Andrade (HOLA) Fortaleza, Brazil) around her study on comparing the effect of cataract surgery and iStent inject, Hydrus micro-stent, or CyPass micro-stent […]
Ticiana De Francesco, AGS 2023: Minimally invasive glaucoma surgery (MiGS) devices in glaucoma management
Minimally invasive glaucoma surgery (MiGS) devices have revolutionised in glaucoma management, achieving reliable IOP reduction with a favorable safety profile and quick postoperative recovery. It was a pleasure to speak with Dr Ticiana De Francesco (Hospital de Olhos Leiria de Andrade (HOLA) Fortaleza, Brazil) to find out her thoughts in the current status of minimally invasive glaucoma […]
Luis Abegão Pinto: World Glaucoma Week 2023
World Glaucoma Week kicks off on 12 March, 2023, with the aim of raising awareness of the impact of this devastating disease. The key to preventing needless vision impairment is prompt diagnosis and treatment. However, many are unaware they have the disease or do not have access to much-needed care. This is particularly true in […]
Journal articles and more to your inbox
Get the latest clinical insights from touchOPHTHALMOLOGYSign me up!